Project Grant R21HL180247
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $462K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $1.669 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for data-consistent motion-correction reconstruction of PET/MR imaging targeting coronary atherosclerotic plaque activity. The research addresses motion artifacts that degrade spatial resolution and quantitative accuracy in coronary PET imaging, particularly for low-count tracers such as 68GA-DOTATATE....
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $850,669 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate place-based drivers of health in sickle cell disease pathogenesis. The project will identify and quantify mechanisms linking neighborhood and personal exposures—including crime-related stressors, unhealthy food access, temperature, airborne particulates, and housing conditions—to clinical...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded Icahn School of Medicine at Mount Sinai $809,307 on July 1, 2026, for a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL183991). The award funds population-based genomic screening for transthyretin amyloidosis (ATTRV), a treatable cardiovascular and neuropathic condition caused by mutations in the TTR gene that disproportionately affects African American and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Icahn School of Medicine at Mount Sinai a $447,977 Project Grant effective September 1, 2025, through August 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The Cardiovascular Science Training Program (CSTP) provides research training and mentorship to pre-doctoral and post-doctoral scientists pursuing independent careers in cardiovascular research. The program delivers...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $149,190 on January 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research into molecular mechanisms by which influenza A virus inhibits lung alveolar defense and promotes secondary bacterial coinfection. The award supports laboratory studies using alveolar epithelial cells and intact alveoli from live lungs to define how influenza A virus induces dephosphorylation...